Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
“Manserin” is a novel peptide originally derived from a larger secretory protein called secretogranin II. A newly published paper suggests that expression of manserin in human prostate cancer tissues may correlate with risk for clinically significant and progressive forms of prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: expression, Gleason, immunohistochemistry, manserin, progression, risk | Leave a Comment »
According to a report in the Science section of the Financial Times, “the world’s first nationwide genetic testing programme for cancer patients goes into action in the UK next month, with support from the public, private and charitable sectors.”
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, expression, gene, genetics, Management, risk | Leave a Comment »
There are in fact three so-called “isozymes” (slightly different versions) of the human enzyme 5α-steroid reductase. The activity of 5α-reductase-II can be affected by the 5α-reductase inhibitor (5-ARI) finasteride (Proscar); the activity of 5α-reductase-I and -II can be affected by the 5-ARI dutasteride (Avodart), but
Filed under: Drugs in development, Prevention | Tagged: 5α-reductase, expression, inhibition | 1 Comment »
As usual, some of our friends in the media are over-hyping a recent publication about the possible effects of a protein called FUS/TLS in the progression of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: expression, FUS, FUS/TLS, progression, protein | Leave a Comment »
A research team at the University of Miami has come up with an innovative new method that (please note the emphasis) might offer a completely new way to eliminate remaining cancer cells in patients with prostate and other types of cancer after first-line therapy.
Filed under: Drugs in development | Tagged: antigen, cancer cell, expression, immunity, tumor | Leave a Comment »
Today’s news reports cover items on: Gene expression and prostate cancer progression Risk of complications from in-office prostate biopsy Post-RALP voiding function Urinary toxicities after IMRT-SIB Drugs in development for CRPC
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: biopsy, CRPC, ERG, expression, gene, IMRT, PTEN, RALP, side effects, toxicity, urinary, voiding | Leave a Comment »
In today’s news reports we discuss: Genetic abnormalities and intermediate risk prostate cancer Ginger tablets to prevent chemotherapy-induced nausea Ixabebilone + mitoxantrone in patients after Taxotere
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: chemotherapy, expression, gene, ginger, intermediate, ixabepilone, mitoxantrone, nausea, risk | Leave a Comment »
There are just two notable reports in today’s early news: On the potential of PMS2 as a prostate cancer marker On age-related cancer outcomes in Europe
Filed under: Diagnosis, Management, Risk, Uncategorized | Tagged: age, expression, outcome, PSM2, survival | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site